New immunotherapy combination tolerable, effective in patients with advanced kidney cancer
A study combining axitinib and pembrolizumab found the treatment to be tolerable and doubling efficacy in patients with advanced kidney cancer. Over 90% of patients exhibited tumor shrinkage, keeping disease under control for over 20 months.